ABSTRACT Plasma noradrenaline, adrenaline, and cyclic 3'5' AMP (cAMP) were measured in seven asthmatic patients with known exercise-induced bronchospasm and six matched non-atopic control subjects during a standard treadmill exercise test and then during matched isocapnic hyperventilation. Normal subjects showed a 5 5 fold rise in noradrenaline and a 3-2 fold rise in adrenaline during exercise compared with a 2-1 fold rise in noradrenaline and no significant rise in adrenaline in asthmatics who all developed bronchoconstriction after exercise (mean fall in peak flow rate 28'4±5*8% 
change in catecholamines in either group suggesting that circulating catecholamines have no direct role in exercise-induced bronchospasm but may play a permissive role via the mast cell.
Beta-adrenoceptor antagonists such as propranolol cause an increase in bronchial tone in asthmatics but not in normal subjects,1 2 suggesting that the airways of asthmatics are under tonic betaadrenoceptor stimulation. However, intrapulmonary sympathetic innervation of airway smooth muscle has not been demonstrated convincingly in man,3 4 and this indicates that pulmonary betaadrenoceptors may be under the control of circulating catecholamines. Few studies have explored the role of circulating catecholamines in asthma partly because of the difficulties in assaying plasma adrenaline and noradrenaline. Recently, a sensitive and specific radioenzymatic assay has been developed5 which we have used in the present study.
Exercise induced asthma (EIA) is a wellrecognised phenomenon but the mechanism remains uncertain. In normal subjects there is a rise in circulating catecholamine levels during exercise,6 7 but it is possible that there may be some abnormality in the catecholamine response to 9 and it is possible to produce similar degrees of bronchoconstriction with matched isocapnic hyperventilation at rest. 10 We therefore compared the plasma catecholamine change occurring in response to exercise and matched hyperventilation in asthmatics with that in non-atopic control subjects.
Methods
Seven male asthmatic patients (all with multiple positive skin tests to common allergens) with known exercise-induced asthma who attended an asthma clinic and six male non-atopic control subjects from a nearby school were studied. There was no significant difference in age, height, weight, or physical fitness between the groups. The mean baseline peak expiratory flow rate (PEFR) of the asthmatics was lower but not significantly different from that of the controls ( 
Results
There was no significant difference between the asthmatic and non-atopic subjects in either maximum minute ventilation or in heart rate increase during exercise (table 2) . There was no significant change in PEFR of controls during or after exercise but in asthmatics, after a small rise during exercise there was a fall in PEFR of 29-4+-58% five minutes after exercise, and return to baseline values 25 minutes later (fig 1) .
There was no significant difference between baseline plasma adrenaline, noradrenaline, or cAMP between the two groups (table 3).In control subjects there was a 5 5 fold rise in noradrenaline and 3-2 fold rise in adrenaline during exercise. However, in asthmatics noradrenaline rose 2 1 fold and there was no significant rise in adrenaline (fig 1) . Plasma cAMP rose 1-4 fold in controls but showed no significant rise in asthmatics (fig 2) . The difference in response between groups was significant (p<0*001) for adrenaline, noradrenaline, and cAMP.
With hyperventilation there was no significant change in PEFR in controls but a mean fall of 29.0-+-5.4% after five minutes in asthmatics. In each individual the fall in PEFR with matched hyperventilation was similar to the fall after exercise. There was no significant change in plasma adrenaline, noradrenaline or cAMP during hyperventilation in either asthmatics or controls. Nor was there any significant rise in adrenaline or nor- fig 3) .
Discussion
All subjects exercised at the same work load and had a similar ventilatory and circulatory response, yet there was a marked difference in catecholamine response between asthmatic and non-atopic control subjects. In controls plasma adrenaline rose threefold during exercise but in asthmatics there was no significant rise, while plasma noradrenaline showed a five-fold rise in controls but only a twofold rise in asthmatics. This impaired catecholamine response to exercise in asthmatics with exercise-induced asthma is difficult to explain. Bronchodilator medication is unlikely to be responsible for the difference since only three of the asthmatics were taking beta-adrenergic treatment.
Moreover salbutamol, when given either orally or by inhalation has had no significant effect on circulating catecholamines in normal subjects (unpublished observations). Circulating noradrenaline is derived mainly from overspill from adrenergic nerves,'3 14 and since the sympathetic innervation of human lung is relatively insignificant,3 it is unlikely that the difference between asthmatics and normal subjects reflects any difference in pulmonary sympathetic innervation. Plasma adrenaline is derived solely from the adrenal medulla. It is possible that the difference is caused by increased clearance of catecholamines in asthmatics. This seems unlikely, since baseline values are not significantly different from the normal subjects and infused adrenaline in asthmatics shows a similar clearance to that in normal subjects (unpublished observations). These results therefore imply a generalised defect in the sympathoadrenal response to exercise in asthmatics who develop EIA. The impaired rise in plasma cAMP during exercise in asthmatics is correlated with the absent rise in circulating adrenaline. These findings are at variance with other studies which report either no difference in catecholamines during exercise between asthmatic and normal subjects,"5 16 or an exaggerated rise during exercise. '7 18 However, in these studies the work load was higher and plasma catecholamines were measured by fluorimetric methods which are relatively insensitive and non-specific in estimating circulating catecholamines. Other studies have shown an impaired rise in free fatty acids after exercise'9 and an impaired rise in plasma cyclic AMP during exercise in asthmatics,20 which would be consistent with an impaired sympatho-adrenal response to exercise in asthmatics.
Is the impaired catecholamine response in asthmatics specific for exercise? Mathe and Knapp demonstrated an impaired catecholamine response to mental stress in asthmatics.2' Insulin tolerance tests in asthmatics provoke a normal hypoglycaemia-induced increase in plasma adrenaline, however, suggesting that the sympatho-adrenal defect may be specific for exercise (unpublished observations).
It is possible that this impaired sympatho-adrenal response to exercise could be important in the pathophysiology of exercise-induced bronchoconstriction. Stimulation of beta-adrenoceptors on pulmonary mast cells inhibits the release of bronchoconstrictor mediators such as histamine and slow-reacting substance of anaphyllaxis.2223 The impaired rise in circulating catecholamines in asthmatics may therefore make release of mediators more likely to occur. It is also possible that the small noradrenaline rise in asthmatics in the absence of a rise in adrenaline may stimulate alpha-adrenoceptors on mast cells causing increased mediator release. 24 In support of this, it has been shown that arterial histamine levels rise during exercise in asthmatics but not in normal subjects. 25 Voluntary hyperventilation caused a similar bronchoconstriction response to the exercise stimulus in asthmatic subjects, yet there was no significant change in circulating catecholamines. This makes it unlikely that circulating catecholamines control bronchial tone directly but it is possible that hyperventilation causes release of mediators from sensitised pulmonary mast cells, which are not protected by a rise in circulating catecholamines.
The reduced sympatho-adrenal response to exercise in asthmatics with EIA, although difficult to explain, may play a role in the pathogenesis of bronchoconstriction by a permissive action on the mast cell. 
